



Express Mail No.: EV452777207US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Qun SUN and Xiaoming ZHOU	Confirmation No.:	6999
Serial No.:	10/669,823	Group Art Unit:	1624
Filed:	September 23, 2003	Examiner:	Balasubramanian, Venkataraman
Title:	THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN	Attorney Docket No.:	6750-157-999
		CAM No.:	305158-999155

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject United States patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application. This Supplemental Information Disclosure Statement supplements the Information Disclosure Statement previously filed on September 23, 2005.

An enclosure accompanying this Supplemental Information Disclosure Statement is A List of References Cited by Applicants and copies of References **C32-C38**.

This Supplemental Information Disclosure Statement is filed under 37 C.F.R. §1.97(c). The fee for this Supplemental Information Disclosure Statement is believed to be \$180.00. The Commissioner is authorized to charge the required fee to Jones Day Deposit Account No. 50-3013.

02/01/2006 RMEBRAHT 00000076 503013 10669823


01 FC:1806 180.00 DA

NYJD: 1609228.1


No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made. 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date: January 27, 2006



Samuel B. Abrams 30,605
JONES DAY (Reg. No.)
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939



Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use several sheets if necessary)ATTY DOCKET NO.
6750-157-999
(CAM No. 305158-999155)APPLICATION NO.
10/669,823APPLICANT:
Qun SUN et al.FILING DATE:
September 23, 2003ART UNIT: CONF. NO.:
1624 6999

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS*	Cite No.	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01				
	A02				
	A03				
	A04				
	A05				

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*	Cite No.	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO
	B01						
	B02						
	B03						
	B04						
	B05						

NON PATENT LITERATURE DOCUMENTS

EXAMINER'S INITIALS*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.
	C32	SZALLASI et al., "The Cloned Rat Vanilloid Receptor VR1 Mediates Both R-Type Binding and C-Type Calcium Response in Dorsal Root Ganglion Neurons," <i>Molec. Pharmacol.</i> 56:581-587 (1999)
	C33	LOPEZ-RODRIQUEZ et al., "VR1 Receptor Modulators as Potential Drugs for Neuropathic Pain," <i>Mini-Reviews in Medicinal Chem.</i> 3(7):729-48 (2003)
	C34	POMONIS et al., "N-(4-Tertiarybutylphenyl)-4-(3-chlorophyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain," <i>J. Pharmacol. Exper. Therapeutics</i> 306(1):387-393 (2003)
	C35	WRIGGLESWORTH et al., "Capsaicin-like Agonists," <i>Drugs of the Future</i> , 23(5):531-38 (1998)
	C36	SZALLASI et al., "Vanilloid (Capsaicin) Receptors and Mechanisms," <i>Pharmacol. Revs.</i> , 51(2):159-211 (1999)
	C37	BEVAN et al., "Vanilloid Receptors: Pivotal Molecules in Nociception," <i>Current Opinions in CPNS Investigational Drugs</i> , 2(2):178-85 (2000)
	C38	WANG et al., "High Affinity Antagonists of the Vanilloid Receptor," <i>Mol. Pharmacol.</i> 62(4):947-56 (2002)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.